Safety and efficacy of venous thromboembolism prophylaxis in patients with cirrhosis: A systematic review and meta‐analysis

Abstract

Background & Aims: Patients with cirrhosis are considered in a haemostatic balance, though weaker than in normal subjects. In these patients, however, the use of pharmacological prophylaxis for venous thromboembolism (VTE) remains controversial.Therefore, in this study, we aimed to assess the safety and efficacy of VTE prophylaxis in patients with cirrhosis. Methods:We conducted a systematic review of studies reporting the occurrence of bleeding and VTE events in patients with cirrhosis, and controls, undergoing VTE prophylaxis. Meta-regression analysis was conducted to further explore the determinants of heterogeneity in the study of the occurrence of either bleeding or VTE events.

Association of abnormal NDUFB2 and UQCRH expression with venous thromboembolism in patients with liver cirrhosis

“…[ 17 – 19 ] Clinically, patients with liver cirrhosis are prone to venous thrombosis. [ 20 ] In patients with liver cirrhosis, the hepatic portal vein reflux is blocked due to the destruction of the hepatic lobular structure, which leads to slow blood flow in the portal vein, local vortex formation, and local platelet aggregation, thereby forming portal vein thrombosis. Thrombosis due to coagulopathy in cirrhosis is a real risk.…”

What are the management considerations for venous thromboembolic events in patients with cirrhosis?

“…A meta-analysis that included more than 5,000 patients lacked suffi cient evidence to advise for or against VTE prophylaxis in patients with cirrhosis, although its use was not associated with signifi cant bleeding risk. 8…”